Get the Stockscreener App
1.85
2.50%
0.05
Cocrystal Pharma Inc stock is traded at $1.85, with a volume of 15,967.
It is up +2.50% in the last 24 hours and up +19.81% over the past month.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).
See More
Previous Close:
$1.80
Open:
$1.82
24h Volume:
15,967
Relative Volume:
0.77
Market Cap:
$18.77M
Revenue:
-
Net Income/Loss:
$-17.93M
P/E Ratio:
-1.0452
EPS:
-1.77
Net Cash Flow:
$-14.28M
1W Performance:
+22.19%
1M Performance:
+19.81%
6M Performance:
-7.29%
1Y Performance:
-19.78%
1-Day Range:
$1.82
$1.9499
1-Week Range:
$1.46
$1.9499
52-Week Range:
$1.12
$3.26
Cocrystal Pharma Inc Stock (COCP) Company Profile
Name
Cocrystal Pharma Inc
Sector
Industry
Phone
(786) 459-1831
Address
19805 N. CREEK PARKWAY, BOTHELL, WA
Compare COCP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
COCP
Cocrystal Pharma Inc
|
1.845 | 15.36M | 0 | -17.93M | -14.28M | -1.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.39 | 117.98B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
566.91 | 58.10B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
316.07 | 42.26B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.38 | 33.42B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
251.66 | 26.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Cocrystal Pharma Inc Stock (COCP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-08-20 | Initiated | H.C. Wainwright | Buy |
Cocrystal Pharma Inc Stock (COCP) Latest News
Cocrystal Pharma (NASDAQ:COCP) Shares Up 14.6% – Here’s What Happened - Defense World
Cocrystal Pharma Announces CDI-988 Presentation at Conference - TipRanks
Farmer Mac (AGM) CFO Aparna Ramesh resigns; Gregory Ramsey named interim | COCP SEC FilingForm 8-K - Stock Titan
Cocrystal Pharma, Inc. to Present Data from Phase 1 Study of First-In-Class Norovirus Protease Inhibitor CDI-988 at the 9th International Calicivirus Conference - MarketScreener
Revolutionary Norovirus Treatment Targets $60B Global Market: Phase 1 Data Reveals New Hope - Stock Titan
10% holder buying at Canaccord Genuity Group (CF) - The Globe and Mail
Cocrystal Pharma Holds 2025 Annual Stockholders Meeting - TipRanks
Biotech Stock Rips Following Key Announcement - The Globe and Mail
Is Citigroup Stock a Buy Now? - The Globe and Mail
Cocrystal Pharma to Present at the H.C. Wainwright Global Investment Conference - The Globe and Mail
Cocrystal Pharma’s CDI-988 Featured at Military Symposium - TipRanks
Military Defense Selects Revolutionary Norovirus Drug: First-Ever Dual Prevention and Treatment Shows Promise - Stock Titan
Bird Flu Vaccine Stocks: 8 Companies Developing H5N1 Vaccines - Investing News Network
What is Zacks Small Cap’s Forecast for COCP FY2025 Earnings? - Defense World
Influenza Pipeline Appears Robust With 120+ Key Pharma - openPR.com
Cocrystal Pharma (COCP) Reports Promising Results with Influenza Inhibitor | COCP Stock News - GuruFocus
Cocrystal Pharma, Inc.'S Investigational Drug Candidate Cc-42344 Demonstrates Strong Antiviral Potency Against the 2024 Highly Pathogenic H5n1 Avian Influenza Strain - marketscreener.com
Cocrystal Pharma’s CC-42344 Shows Strong Antiviral Potency - TipRanks
Cocrystal’s flu drug shows promise against H5N1 strain - Investing.com Australia
Pre-market Movers: ALZN, HCTI, REVB, NTLA... - RTTNews
Cocrystal Pharma's CC-42344 Shows Strong Antiviral Potency Against 2024 H5n1 Avian Influenza Strain - marketscreener.com
Cocrystal Pharma's Investigational Drug Candidate CC-42344 Demonstrates Strong Antiviral Potency Against the 2024 Highly Pathogenic H5N1 Avian Influenza Strain - The Manila Times
ARB IOT Group Limited Announces 1-for-15 Reverse Share Split - The Manila Times
Upexi Partners with Crypto-Native Marketing and Design Firm, GMI Digital, to Drive Solana-Focused Strategy - The Manila Times
Breakthrough: New Drug Crushes Tamiflu Efficacy in Fighting Dangerous Bird Flu Strain, Lab Study Shows - Stock Titan
Context Therapeutics to Appoint Dr. Karen Chagin, M.D. as Chief Medical Officer - The Manila Times
Cocrystal Pharma to Participate in Noble Capital Markets' 2025 Emerging Growth Virtual Equity Conference - The Manila Times
Cocrystal Pharma Announces Exclusive Investor Access: Live Q&A and One-on-One Meetings at Noble Conference - Stock Titan
COCP: Topline Results for High-Dose Cohort from Phase 1 Trial of CDI-988 Expected in 2Q25… - MSN
What is Noble Financial’s Estimate for COCP Q2 Earnings? - Defense World
Cocrystal Pharma Reports First Quarter 2025 Financial Results an - GuruFocus
Cocrystal Pharma Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Cocrystal Pharma (COCP) Advances CDI-988 for Norovirus Treatment - GuruFocus
Cocrystal Pharma Reports First Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs - The Manila Times
Cocrystal Pharma (COCP) Advances CDI-988 for Norovirus Treatment | COCP Stock News - GuruFocus
Breakthrough: Cocrystal's Novel Antiviral CDI-988 Demonstrates Superior Activity Against All Major Norovirus Variants - Stock Titan
Cocrystal Pharma (COCP) Projected to Post Earnings on Monday - Defense World
Cocrystal Pharma's Novel Norovirus Antiviral to Be Presented at Department of Defense Medical Conference - MarketScreener
Norovirus Infection Pipeline: 8+ Leading Companies Advancing - openPR.com
Cocrystal Pharma (COCP) Advances Norovirus Drug Candidate CDI-98 - GuruFocus
Press Release Distribution & PR Platform - ACCESS Newswire
Hepatitis C Virus Infection Pipeline: 20+ Leading Companies - openPR.com
Cocrystal Pharma (NASDAQ:COCP) Stock Price Up 3.3% – Here’s Why - Defense World
Cocrystal Pharma Advances Norovirus Antiviral Candidate CDI-988 - TipRanks
Cocrystal Pharma's Norovirus Oral Antiviral Candidate Demonstrates Potent Activity Against the Emerging GII.17 Variants - The Manila Times
First-Ever Norovirus Treatment Tackles Dominant 2024 Variants: $60B Market Opportunity - Stock Titan
Cocrystal Pharma Presents to Investment Community - TipRanks
Aytu BioPharma Stock Price, Quotes and Forecasts - Benzinga
Cocrystal Pharma to Present at Life Science Innovation Northwest 2025 Conference - The Manila Times
Cocrystal Pharma CEO to Reveal Latest Developments at Elite Northwest Biotech Summit - Stock Titan
Addex Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:ADXN - Benzinga
Cocrystal Pharma Inc Stock (COCP) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.07%
0.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):